Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease

References

• Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574–651
   PubMed Web of Science ®Google Scholar
• Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532–539
   PubMed Web of Science ®Google Scholar
• Ho PM, Tsai TT, Wang TY, Shetterly SM, Clarke CL, Go AS, Sedrakyan A, Rumsfeld JS, Peterson ED, Magid DJ. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes 2010;3:303–308
   PubMed Web of Science ®Google Scholar
• Kozinski M, Bielis L, Wisniewska-Szmyt J, Sukiennik A, Grabczewska Z, Swiatkiewicz I, Ziołkowski M, Rość D, Kubica J. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. Cardiol J 2008;15:530–536
   PubMed Web of Science ®Google Scholar
• Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: An adjustment for platelet count is not necessary. J Thromb Haemost 2008;6:677–683
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Palisaitis DA, Schampaert E, Diodati JG. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res 2009;124:546–553
   PubMed Web of Science ®Google Scholar
• Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005;46:638–645
   PubMed Web of Science ®Google Scholar
• Grines CL, Bonow RO, Casey DE, Jr Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P; American Heart Association; American College of Cardiology, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813–818
   Google Scholar
• Lordkipanidzé M, Diodati JG, Pharand C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence. Pharmacol Ther 2009;123:178–186
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584–2591
   PubMed Web of Science ®Google Scholar
• Mylotte D, Peace A, Tedesco T, Mangiacapra F, Dicker P, Kenny D, Foley DP. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 2011;9:24–32
   PubMed Web of Science ®Google Scholar
• Diehl P, Halscheid C, Olivier C, Helbing T, Bode C, Moser M. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol 2011;100:765–771
   PubMed Web of Science ®Google Scholar
• Sambu N, Dent H, Englyst N, Warner TD, Leadbeater P, Roderick P, Gray H, Simpson I, Corbett S, Calver A, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart 2011;97:1661–1667
   PubMed Web of Science ®Google Scholar
• Djukanovic N, Todorovic Z, Obradovic S, Njegomirovic S, Zamaklar-Trifunovic D, Protic D, Ostojic M. Clopidogrel cessation triggers aspirin rebound in patients with coronary stent. J Clin Pharm Ther 2014;39:69–72
   PubMed Web of Science ®Google Scholar
• Ford I, Scott NW, Herd V, Mitchell LR, Williams DJ, Brittenden J. A randomized controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease. J Am Coll Cardiol 2014;63:233–239
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Barnard MR, Fox ML, Michelson AD. The Platelet Activity After Clopidogrel Termination (PACT) Study. Circ Cardiovasc Interv 2010;3:442–449
   PubMed Web of Science ®Google Scholar
• Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Seyfarth M, Kastrati A, von Beckerath N, Schömig A. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 2010;55:558–565
   PubMed Web of Science ®Google Scholar
• Fiedler KA, Mehilli J, Kufner S, Schlichting A, Ibrahim T, Sibbing D, Ott I, Schunkert H, Laugwitz KL, Kastrati A, Schulz S. Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy – ISAR-CAUTION. Thromb Haemost 2014;111:1041–1049
   PubMed Web of Science ®Google Scholar
• Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006;98:681–684
   PubMed Web of Science ®Google Scholar
• Price MJ, Teirstein PS. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. Am J Cardiol 2008;102:790–795
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Harrison P. Beware of being caught on the rebound. J Thromb Haemost 2011;9:21–23
   PubMed Web of Science ®Google Scholar
• Harrison P, Mackie I, Mathur A, Robinson MS, Hong Y, Erusalimsky JD, Machin SJ, Martin JF. Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 2005;16:557–562
   PubMed Web of Science ®Google Scholar
• Bath PM, Gladwin AM, Carden N, Martin JF. Megakaryocyte DNA content is increased in patients with coronary artery atherosclerosis. Cardiovasc Res 1994;28:1348–1352
   PubMed Web of Science ®Google Scholar
• van der Loo B, Martin JF. A role for changes in platelet production in the cause of acute coronary syndromes. Arterioscler Thromb Vasc Biol 1999;19:672–679
   PubMed Web of Science ®Google Scholar
• Hjemdahl P, Olsson G. Rebound phenomena following withdrawal of long-term beta-adrenoceptor blockade. Acta Med Scand Suppl 1982;665:43–47
   PubMedGoogle Scholar
• Ferratini M. Risk of rebound phenomenon during nitrate withdrawal. Int J Cardiol 1994;45:89–96
   PubMed Web of Science ®Google Scholar
• Cunningham MR, Nisar SP, Mundell SJ. Molecular mechanisms of platelet P2Y(12) receptor regulation. Biochem Soc Trans 2013;41:225–230
   PubMed Web of Science ®Google Scholar
• Tolhurst G, Vial C, Leon C, Gachet C, Evans RJ, Mahaut-Smith MP. Interplay between P2Y(1), P2Y(12), and P2X(1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. Blood 2005;106:1644–1651
   PubMed Web of Science ®Google Scholar
• Shanker G, Kontos JL, Eckman DM, Wesley-Farrington D, Sane DC. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis 2006;22:213–220
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kwon JA, Cho SA, Jarrar YB, Shin JG. Effects of testosterone and 17beta-oestradiol on expression of the G protein-coupled receptor P2Y12 in megakaryocytic DAMI cells. Platelets 2012;23:579–585
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable cornonary disease: The ONSET/OFFSET study. Circulation 2009;120:2577–2585
   PubMed Web of Science ®Google Scholar
• Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 2007;5:82–90
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008;29:2877–2885
   PubMed Web of Science ®Google Scholar